 |
51 Diseases |  |
19 Trials |
|
19 Trials |  |
449 News |  |
| «12345678» |
- | sorafenib / Generic mfg.
Enrollment closed, Surgery, Metastases: Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 19, 2015
P2, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Enrollment change, Trial primary completion date: HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=10, Completed, Sponsor: Carolinas Healthcare System
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=60 --> 10 | Trial primary completion date: Jan 2009 --> Jul 2012
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Trial primary completion date, Metastases: Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases (clinicaltrials.gov) - Dec 22, 2014
P2, N=42, Completed, Sponsor: Nicholas Fidelman
Enrolling by invitation --> Completed | N=60 --> 10 | Trial primary completion date: Jan 2009 --> Jul 2012 Terminated --> Completed | Trial primary completion date: Jan 2014 --> Oct 2013
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed, Metastases: Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases (clinicaltrials.gov) - Nov 12, 2014
P1, N=30, Active, not recruiting, Sponsor: Northwestern University
Terminated --> Completed | Trial primary completion date: Jan 2014 --> Oct 2013 Recruiting --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Surgery: Y-90HDE: Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=400, Enrolling by invitation, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting N=250 --> 400
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Oct 20, 2014
P0, N=12, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=250 --> 400 Suspended --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed, Trial primary completion date: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Aug 21, 2014
P2, N=58, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Mar 2015
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date: Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors (clinicaltrials.gov) - Aug 7, 2014
P2, N=50, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Mar 2015 Trial primary completion date: Mar 2014 --> Aug 2014
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Trial withdrawal: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease (clinicaltrials.gov) - Jul 23, 2014
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2014 --> Aug 2014 N=22 --> 0 | Not yet recruiting --> Withdrawn
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed: Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma (clinicaltrials.gov) - Jul 16, 2014
P2, N=41, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=22 --> 0 | Not yet recruiting --> Withdrawn Suspended --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial suspension: Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma (clinicaltrials.gov) - Jun 26, 2014
P2, N=41, Suspended, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Suspended --> Active, not recruiting Recruiting --> Suspended
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial suspension, Metastases: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Jun 3, 2014
P0, N=12, Suspended, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Recruiting --> Suspended
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date: TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis (clinicaltrials.gov) - May 22, 2014
P=N/A, N=35, Completed, Sponsor: Emory University
Recruiting --> Suspended Trial primary completion date: Oct 2013 --> Jan 2014
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion date: TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis (clinicaltrials.gov) - May 22, 2014
P=N/A, N=35, Completed, Sponsor: Emory University
Trial primary completion date: Oct 2013 --> Jan 2014 Trial completion date: Dec 2017 --> Jan 2014
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change: TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis (clinicaltrials.gov) - May 22, 2014
P=N/A, N=35, Completed, Sponsor: Emory University
Trial completion date: Dec 2017 --> Jan 2014 N=100 --> 35
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion: TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis (clinicaltrials.gov) - May 22, 2014
P=N/A, N=35, Completed, Sponsor: Emory University
N=100 --> 35 Recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date: Study of Gemcitabine With TheraSphere (clinicaltrials.gov) - May 22, 2014
P1, N=9, Terminated, Sponsor: Hyun Kevin Kim
Recruiting --> Completed Trial primary completion date: Sep 2013 --> Jan 2014
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial termination: Study of Gemcitabine With TheraSphere (clinicaltrials.gov) - May 22, 2014
P1, N=9, Terminated, Sponsor: Hyun Kevin Kim
Trial primary completion date: Sep 2013 --> Jan 2014 Recruiting --> Terminated; PI moved to different institution
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change: Study of Gemcitabine With TheraSphere (clinicaltrials.gov) - May 22, 2014
P1, N=9, Terminated, Sponsor: Hyun Kevin Kim
Recruiting --> Terminated; PI moved to different institution N=24 --> 9
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date, Pre-transplantation: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma (clinicaltrials.gov) - May 11, 2014
P1, N=40, Active, not recruiting, Sponsor: Northwestern University
N=24 --> 9 Trial primary completion date: Jul 2014 --> Dec 2014
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion date, Pre-transplantation: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma (clinicaltrials.gov) - May 11, 2014
P1, N=40, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Jul 2014 --> Dec 2014 Trial completion date: Jul 2014 --> Dec 2015
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date, Surgery, Metastases: Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 8, 2014
P2, N=500, Recruiting, Sponsor: Northwestern University
Trial completion date: Jul 2014 --> Dec 2015 Trial primary completion date: Apr 2014 --> Apr 2015
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion date, Surgery, Metastases: Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 8, 2014
P2, N=500, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Apr 2014 --> Apr 2015 Trial completion date: Apr 2015 --> Apr 2016
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment open: Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma (clinicaltrials.gov) - Feb 24, 2014
P2, N=41, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Apr 2015 --> Apr 2016 Suspended --> Recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial initiation date: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease (clinicaltrials.gov) - Jan 20, 2014
P1, N=22, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Initiation date: Nov 2013 --> May 2014
- | TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Surgery, Metastases: Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 10, 2013
P3, N=120, Completed, Sponsor: University of Pittsburgh
Initiation date: Nov 2013 --> May 2014 Active, not recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment open: MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) - Nov 14, 2013
P2, N=41, Recruiting, Sponsor: Center Eugene Marquis
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial termination: Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 20, 2013
P2, N=14, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Recruiting Recruiting --> Terminated; Off study clinical use of Y90 glass microspheres (TheraSphere)
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change: Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 20, 2013
P2, N=14, Terminated, Sponsor: University of California, San Francisco
Recruiting --> Terminated; Off study clinical use of Y90 glass microspheres (TheraSphere) N=30 --> 14
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial termination, Metastases: Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases (clinicaltrials.gov) - Oct 20, 2013
P2, N=41, Terminated, Sponsor: Nicholas Fidelman
N=30 --> 14 Enrolling by invitation --> Terminated
- ||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion: TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Oct 17, 2013
P=N/A, N=150, Completed, Sponsor: University of Louisville
Enrolling by invitation --> Terminated Recruiting --> Completed
- | sorafenib / Generic mfg.
Enrollment open, Surgery, Metastases: Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 12, 2013
P2, N=20, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P2 trial: MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) - Jul 28, 2013
P2, N=41, Recruiting, Sponsor: Center Eugene Marquis
- | sorafenib / Generic mfg.
New P2 trial, Surgery, Metastases: Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 14, 2013
P2, N=20, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | TheraSphere (yttrium 90 microspheres) / Boston Scientific, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
New P2 trial, Metastases: Definitive Therapy for Oligometastatic Solid Malignancies (clinicaltrials.gov) - Jul 11, 2013
P2, N=110, Recruiting, Sponsor: Rocky Mountain Cancer Centers
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed: Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors (clinicaltrials.gov) - Jun 20, 2013
P2, N=50, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial initiation date, IO biomarker: TheraSphere (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=130, Recruiting, Sponsor: University of California, Irvine
Recruiting --> Active, not recruiting Initiation date: Jun 2001 --> May 2002
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P1 trial: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease (clinicaltrials.gov) - May 27, 2013
P1, N=22, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Surgery: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 5, 2013
P2, N=55, Completed, Sponsor: City of Hope Medical Center
Initiation date: Jun 2001 --> May 2002 N=100 --> 55
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Surgery: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 5, 2013
P2, N=55, Completed, Sponsor: City of Hope Medical Center
N=100 --> 55 Active, not recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed, Pre-transplantation: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 2, 2013
P1, N=40, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Metastases: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Dec 20, 2012
P0, N=12, Recruiting, Sponsor: Case Comprehensive Cancer Center
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Metastases: Use of TheraSphere (clinicaltrials.gov) - Dec 9, 2012
P1/2, N=81, Completed, Sponsor: Southwestern Regional Medical Center
Not yet recruiting --> Recruiting N=50 --> 81
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Metastases: Use of TheraSphere (clinicaltrials.gov) - Dec 9, 2012
P1/2, N=81, Completed, Sponsor: Southwestern Regional Medical Center
N=50 --> 81 Active, not recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment open: Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 22, 2012
P=N/A, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P2 trial: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Apr 18, 2012
P2, N=58, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- |||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment open: STOP-HCC: Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (clinicaltrials.gov) - Apr 1, 2012
P3, N=400, Recruiting, Sponsor: BTG International Inc.
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=100, Recruiting, Sponsor: Emory University
- |||||||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P3 trial: STOP-HCC: Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (clinicaltrials.gov) - Mar 14, 2012
P3, N=400, Recruiting, Sponsor: BTG International Inc.
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change: Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 12, 2012
P=N/A, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=25 --> 200